MacroGenics Inc. MGNX announced on Tuesday that it reviewed data accumulated from the TAMARACK Phase 2 study of vobramitamab duocarmazine (vobra duo). In May, when the company released interim data from the trial, MacroGenics reported five deaths (fatal outcome) during the trial. After reviewing, MacroGenics agreed with the study's Independent Data Monitoring Committee's recommendation to discontinue the treatment for the remaining metastatic castration-resistant prostate cancer (mCRPC) study participants w ...

NEW YORK, July 31, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in MacroGenics, Inc. ("MacroGenics" or the "Company") (NASDAQ: MGNX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of MacroGenics investors who were adversely affected by alleged securities fraud between March 7, 2024 and May 9, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/macrogenics-inc-lawsuit- ...

Macrogenics (NASDAQ:MGNX) stock is dropping on Wednesday as the biopharmaceutical company prepares to discontinue a clinical trial of vobramitamab duocarmazine. How This Affects MGNX Stock On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines. Scott Koenig, M.D., Ph.D., president and CEO of MacroGeni ...

SAN DIEGO, July 30, 2024 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired MacroGenics, Inc. (NASDAQ: MGNX) common stock between March 7, 2024 and May 9, 2024. MacroGenics is a biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Allegations: Robbins LLP is Investigatin ...

On May 9, 2024, MacroGenics announced in a press release that a total of five fatal outcomes had occurred in its TAMARACK Phase 2 study of vobramitamab duocarmazine in patients with metastatic astration resistant prostate cancer. On this news, the price of MacroGenics shares declined by $11.36 per share, or approximately 77.4%, from $14.67 per share on May 9, 2024 to close at $3.31 on May 10, 2024. If you purchased or otherwise acquired MacroGenics shares and suffered a loss, are a long-term stockholder, ha ...

NEW YORK, July 30, 2024 (GLOBE NEWSWIRE) -- SO WHAT: If you purchased stock or sold puts of MacroGenics during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adver ...

Abstract of clinical data accepted for poster presentation at ESMO Congress 2024 in September ESMO poster to include protocol-defined TAMARACK Phase 2 mCRPC study data, including predefined landmark primary endpoint of 6-month rPFS rate and updated safety Treatment recently discontinued for TAMARACK mCRPC study participants who remained eligible for further dosing following review of totality of data, including efficacy, and emerging adverse events associated with prolonged exposure and considering potentia ...

ROCKVILLE, MD, July 30, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced the achievement of $100 million in milestones from Incyte Corporation related to development progress of ZYNYZ® (retifanlimabdlwr), following an agreement on July 24, 2024, pursuant to which certain milestones were deemed to have been met. ZYNYZ i ...

Under the 2017 collaboration agreement with Incyte, MacroGenics received an upfront payment of $150 million and has achieved a total of $215 million in milestones, including the recent $100 million described above. MacroGenics remains eligible to receive up to a total of $210 million in potential development and regulatory milestones and up to $330 million in potential commercial milestones. MacroGenics receives tiered royalties, which range from 15 to 24 percent, on worldwide net sales of ZYNYZ. About Macr ...

NEW YORK, July 30, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against MacroGenics, Inc. ("MacroGenics" or "the Company") (NASDAQ: MGNX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired MacroGen ...